III CFA - Checkpoint Therapeutics CEO Pres

Checkpoint Therapeutics Management Efficiency

The company has return on total asset (ROA) of (3.167) % which means that it has lost $3.167 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.2038) %, meaning that it created substantial loss on money invested by shareholders. Checkpoint Therapeutics' management efficiency ratios could be used to measure how well Checkpoint Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Checkpoint Therapeutics' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 4.17 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (9.16). Change To Liabilities is likely to gain to about 22.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.9 M in 2024.

Similar Executives

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Checkpoint Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. Checkpoint Therapeutics (CKPT) is traded on NASDAQ Exchange in USA. It is located in 95 Sawyer Road, Waltham, MA, United States, 02453 and employs 23 people. Checkpoint Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Checkpoint Therapeutics Management Team

Checkpoint Stock Performance Indicators

Additional Tools for Checkpoint Stock Analysis